Search

Your search keyword '"Vioxx (Medication) -- Evaluation"' showing total 31 results
Start Over Descriptor "Vioxx (Medication) -- Evaluation"
31 results on '"Vioxx (Medication) -- Evaluation"'

1. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial

Author

Buvanendran, Asokumar, Kroin, Jeffrey S., Tuman, Kenneth J., Lubenow, Timothy R., Elmofty, Dalia, Moric, Mario, and Rosenberg, Aaron G.

Subjects
Vioxx (Medication) -- Evaluation, Pain, Postoperative -- Drug therapy, Rofecoxib -- Evaluation
Abstract

A COX-2 inhibitor before and after surgery can reduce pain in patients who have knee replacement surgery, according to a study of 70 patients. The patients who took Vioxx had less pain and needed less physical therapy compared to those who took a placebo, or inactive substance. They were also less likely to experience nausea and vomiting or to have difficulty sleeping.

Published
2003

2. Selecting ne drugs for pain control: evidence-based decisions or clinical impressions?

Author

Jeske, Arthur H.

Subjects
Pain, Postoperative -- Drug therapy, Rofecoxib -- Evaluation, Health, Vioxx (Medication) -- Evaluation
Abstract

The COX-2 inhibitor rofecoxib (Vioxx) is no more effective than NSAIDs in treating postoperative dental pain in the short term but may be acceptable for treating long-term pain. This is because it has fewer long-term side effects than NSAIDs.

Published
2002

3. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis

Author

Bombardier, Claire, Laine, Loren, Reicin, Alise, Shapiro, Deborah, Burgos-Vargas, Ruben, Davis, Barry, Day, Richard, Ferraz, Marcos Bosi, Hawkey, Christopher J., Hochberg, Marc C., Kvein, Tore K., and Schnitzer, Thomas J.

Subjects
Vioxx (Medication) -- Evaluation, Rheumatoid arthritis -- Drug therapy, Rofecoxib -- Evaluation
Abstract

The COX-2 inhibitor rofecoxib (Vioxx) has fewer gastrointestinal side effects than the non-steroidal anti-inflammatory drug naproxen. In a study of 8,076 patients with rheumatoid arthritis, rofecoxib was as effective as naproxen but caused only half the number of gastrointestinal side effects.

Published
2000

5. The Vioxx story: would it have ended differently in the European Union?

Author

Thomas, W. John

Subjects
Vioxx (Medication) -- Evaluation, Warning labels -- Laws, regulations and rules, Products liability -- Laws, regulations and rules, Government regulation
Abstract

I. INTRODUCTION The rise and fall of the pain-killer Vioxx is one of the most remarkable marketing stories in pharmaceutical history. A true riches to rags tale, its events unfolded [...]

Published
2006

6. The FDA defense: Vioxx and the argument against federal preemption of state claims for injuries resulting from defective drugs.

Author

O'Steen, Jonathan V. and O'Steen, Van

Subjects
Vioxx (Medication) -- Evaluation, Exclusive and concurrent legislative powers -- Health aspects, Products liability -- Laws, regulations and rules, Failure to warn (Law) -- Laws, regulations and rules, Product safety -- Laws, regulations and rules, United States. Food and Drug Administration -- Powers and duties, Government regulation
Published
2006

7. Rethinking and restructuring the FDA drug approval process in light of the Vioxx recall.

Author

Dohman, Amanda

Subjects
Vioxx (Medication) -- Evaluation, Drug approval -- Methods, Product recalls -- Laws, regulations and rules, Products liability -- Laws, regulations and rules, Merck & Company Inc. -- Cases, United States. Food and Drug Administration -- Powers and duties, Product recall, Government regulation, Company legal issue
Published
2005

8. Safety of COX-2 Inhibitors

Author

Kubetin, Sally Koch

Subjects
Celebrex (Medication) -- Evaluation, Vioxx (Medication) -- Evaluation, COX-2 inhibitors -- Evaluation
Abstract

The cyclooxygenase-2 inhibitors are not superaspirins, but they are safer aspirins, Dr. David H. Corner said at the annual meeting of the Colorado chapter of the American College of Physicians--American [...]

Published
2000

9. COX-2 Inhibitors Are 'Safer Aspirins,' Not 'Superaspirins'

Author

JANCIN, BRUCE

Subjects
Celebrex (Medication) -- Evaluation, Vioxx (Medication) -- Evaluation, COX-2 inhibitors -- Evaluation
Abstract

COLORADO SPRINGS -- The cyclooxygenase-2 inhibitors are not "superaspirins," but they are "safer aspirins," Dr. David H. Collier said at the annual meeting of the Colorado chapter of the American [...]

Published
2000

10. Vioxx might control postoperative knee pain

Subjects
Rofecoxib -- Evaluation, Health, Vioxx (Medication) -- Evaluation
Abstract

Oral rofecoxib (Vioxx) may have a role in controlling postoperative pain patients undergoing knee surgery. Researchers in Chicago enrolled 70 patients who were undergoing total knee arthroplasty and randomized them [...]

Published
2004

11. EDITORIAL: learning from Vioxx

Subjects
United States. Food and Drug Administration -- Powers and duties -- Management, Product recalls -- Laws, regulations and rules, Drug approval -- Laws, regulations and rules, Product safety -- Management -- Laws, regulations and rules, Government regulation, Company business management, Product recall, Business, General interest, Business, regional, Vioxx (Medication) -- Evaluation
Abstract

Nov. 14--THE RECALL in 2004 of Vioxx after the arthritis pain reliever was found to cause heart attacks and strokes is just one example of a drug that the Food [...]

Published
2006

12. Only a few months of Vioxx could harm heart, journal says

Author

Henderson, Diedtra

Subjects
United States. Food and Drug Administration -- Management -- Evaluation, Heart diseases -- Care and treatment, Actions and defenses -- Health aspects, Periodicals -- Evaluation, Company business management, Lawsuit/litigation, Business, General interest, Business, regional, Vioxx (Medication) -- Evaluation
Abstract

Byline: Diedtra Henderson Jun. 27--WASHINGTON -- In an action that could hamper Merck & Co.'s ability to defend itself against thousands of lawsuits, a prominent journal yesterday published a correction [...]

Published
2006

13. High-dose rofecoxib confirmed prothrombotic, study shows. (Pharmacology Watch)

Author

Elliott, William T.

Subjects
COX-2 inhibitors -- Physiological aspects, COX-2 inhibitors -- Evaluation, Rofecoxib -- Physiological aspects, Rofecoxib -- Evaluation, Health, Vioxx (Medication) -- Evaluation
Abstract

Debate over the cardiovascular effects of COX-2 inhibitors has raged for more than a year since a special communication was published in JAMA last August (JAMA. 2001;286: 954-959) suggesting an [...]

Published
2002

14. High-dose refecoxib confirmed prothrombotic, study shows. (Pharmacology Watch)

Subjects
COX-2 inhibitors -- Adverse and side effects, COX-2 inhibitors -- Physiological aspects, Rofecoxib -- Adverse and side effects, Rofecoxib -- Physiological aspects, Prostacyclin -- Physiological aspects, Losartan -- Evaluation, Heart enlargement -- Drug therapy, Lisinopril -- Evaluation, Perfusion (Physiology) -- Physiological aspects, Quinolone antibacterial agents -- Evaluation, Coronary heart disease -- Prevention, Warfarin -- Evaluation, Heart attack -- Care and treatment, Lung diseases, Obstructive -- Drug therapy, Quinolones, Herpes simplex -- Care and treatment, Health, Vioxx (Medication) -- Evaluation, Valtrex (Medication) -- Evaluation, Spiriva (Medication) -- Evaluation, Lariam (Medication) -- Evaluation
Abstract

Debate over the cardiovascular effects of COX-2 inhibitors has raged for more than a year since a special communication was published in JAMA last August (JAMA. 2001;286: 954-959) suggesting an [...]

Published
2002

15. COX-2 inhibitors face marketing challenges. (Newswire)

Subjects
Merck & Company Inc. -- Product information, Pharmaceutical industry -- Product information, Business, Health care industry, Celebrex (Medication) -- Evaluation, Vioxx (Medication) -- Evaluation
Abstract

A differentiation between the two leading COX-2 inhibitors, Celebrex and Vioxx, has been established after more than two years on the market, but the changes may lead to gastric distress [...]

Published
2002

16. BUSINESS DIGEST

Subjects
Company legal issue, Company financing, Company bankruptcy, Northwest Airlines Inc. -- Finance, Delta Air Lines Inc. -- Finance, United States. Food and Drug Administration -- Investigations, Vioxx (Medication) -- Evaluation, Medical equipment -- Evaluation -- Supply and demand, Gasoline -- Supply and demand -- Evaluation, Bankruptcy reorganizations -- Investigations, Physiological apparatus -- Evaluation -- Supply and demand, Airlines -- Finance -- Investigations -- Political activity -- Supply and demand
Abstract

Two Airlines, Delta and Northwest, File for Bankruptcy Court Protection Northwest, the nation's fifth-largest airline, filed for bankruptcy protection, a step taken simultaneously by Delta Air Lines, the country's third-largest […]

Published
2005

17. Other ways to ease pain from arthritis

Author

Davis, Robert J.

Subjects
Arthritis -- Drug therapy, Glucosamine -- Evaluation, Chondroitin -- Evaluation, Business, Business, general, Vioxx (Medication) -- Evaluation, Celebrex (Medication) -- Evaluation
Published
2002

18. Panel approves Merck's claim for arthritis drug

Author

Harris, Gardiner and Carroll, Jim

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Merck & Company Inc. -- Product information, Pharmaceutical industry -- Product information, Arthritis -- Drug therapy, Business, Business, general, Vioxx (Medication) -- Evaluation
Published
2001

19. Panel calls for FDA reform, changes in design of trials

Author

Schneider, Mary Ellen

Subjects
Vioxx (Medication) -- Evaluation, Clinical trials -- Analysis, Rofecoxib -- Evaluation, Prescription Drug User Fee Act of 1992
Abstract

BOSTON -- Any proposals to reform the Food and Drug Administration should meet the test that the changes would have prevented the arthritis drug Vioxx from getting to the market, [...]

Published
2006

20. Vioxx might control postoperative knee pain

Author

Elliott, William T.

Subjects
Antiarthritic agents -- Evaluation, Pain, Postoperative -- Care and treatment, Rofecoxib -- Evaluation, Health, Vioxx (Medication) -- Evaluation
Abstract

Oral rofecoxib (Vioxx) may have a role in controlling postoperative pain patients undergoing knee surgery. Researchers in Chicago enrolled 70 patients who were undergoing total knee arthroplasty and randomized them [...]

Published
2004

21. Vioxx might control postoperative knee pain

Author

Elliott, William T.

Subjects
Pain, Postoperative -- Care and treatment, Rofecoxib -- Evaluation, Health, Vioxx (Medication) -- Evaluation
Abstract

Oral rofecoxib (Vioxx) may have a role in controlling postoperative pain patients undergoing knee surgery. Researchers in Chicago enrolled 70 patients who were undergoing total knee arthroplasty and randomized them [...]

Published
2004

22. Vioxx beats Celebrex in acute pain?

Subjects
Merck & Company Inc. -- Evaluation, G.D. Searle and Co. -- Evaluation, Pharmaceutical industry -- Evaluation, Business, Pharmaceuticals and cosmetics industries, Vioxx (Medication) -- Evaluation, Celebrex (Medication) -- Evaluation
Abstract

A Merck & Co. 1999 study shows that dental patients receiving a 50 mg dose of Vioxx for relief of pain caused by surgery to remove two or more molars experienced faster pain relief onset and longer duration of action than patients who had received 200mg of Searle's Celebrex.

Published
1999

24. New Treatments for Osteoarthritis

Subjects
Vioxx (Medication) -- Evaluation, Celebrex (Medication) -- Evaluation, Feldene (Medication) -- Evaluation, Voltaren (Medication) -- Evaluation, Osteoarthritis -- Care and treatment, Drugs -- Evaluation
Abstract

CHANCES ARE you've heard about new medications for osteoarthritis, the degenerative joint disease that afflicts some 21 million Americans. The two drugs, Vioxx (rofecoxib), and Celebrex (celecoxib), have been getting [...]

Published
2001

25. Vioxx for chronic pain

Subjects
Rofecoxib -- Evaluation, Backache -- Care and treatment, Intractable pain -- Care and treatment, Health, Vioxx (Medication) -- Evaluation
Published
2003

27. Vioxx might control postoperative knee pain

Author

Elliott, William T.

Subjects
Antiarthritic agents -- Evaluation, Pain, Postoperative -- Care and treatment, Rofecoxib -- Evaluation, Health, Vioxx (Medication) -- Evaluation
Abstract

Oral rofecoxib (Vioxx) may have a role in controlling postoperative pain patients undergoing knee surgery. Researchers in Chicago enrolled 70 patients who were undergoing total knee arthroplasty and randomized them [...]

Published
2004

28. Vioxx might control postoperative knee pain

Author

Elliott, William T.

Subjects
Pain, Postoperative -- Care and treatment, Rofecoxib -- Evaluation, Health, Psychology and mental health, Vioxx (Medication) -- Evaluation
Abstract

Oral rofecoxib (Vioxx) may have a role in controlling postoperative pain patients undergoing knee surgery. Researchers in Chicago enrolled 70 patients who were undergoing total knee arthroplasty and randomized them [...]

Published
2004

29. Vioxx might control postoperative knee pain

Author

Elliott, William T.

Subjects
Pain, Postoperative -- Drug therapy, Health, Vioxx (Medication) -- Evaluation
Abstract

Oral rofecoxib (Vioxx) may have a role in controlling postoperative pain patients undergoing knee surgery. Researchers in Chicago enrolled 70 patients who were undergoing total knee arthroplasty and randomized them [...]

Published
2004

30. NSAIDs & Alzheimer's

Subjects
Aleve (Medication) -- Evaluation, Vioxx (Medication) -- Evaluation, Nonsteroidal anti-inflammatory drugs -- Dosage and administration, Nonsteroidal anti-inflammatory drugs -- Evaluation, Alzheimer's disease -- Drug therapy
Abstract

Two popular non-steroidal anti-inflammatory drugs (NSAIDs) failed to slow dementia in a study of 351 patients with mild-to-moderate Alzheimer's disease. In the first large-scale trial on NSAIDs and Alzheimer's, patients [...]

Published
2003

31. COX-2s no safer than other NSAIDs? (The Back Page)

Subjects
Merck & Company Inc. -- Product information, COX-2 inhibitors -- Evaluation, Nonsteroidal anti-inflammatory drugs -- Evaluation, Health, Vioxx (Medication) -- Evaluation
Published
2001

Catalog

Books, media, physical & digital resources
See catalog results